Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401
Stemline Therapeutics announced that it has initiated its rolling submission of a Biologics License Application (BLA) for SL-401 to the U.S. Food and Drug Administration (FDA). SL-401…
Read More...
Read More...
